Skip to content
Sign in

ICCC · NASDAQ

ImmuCell (ICCC) Stock Price & Fundamentals

$561.62−0.65%−$3.68End-of-day price as of Oct 9, 2026

ImmuCell (ICCC) closed at $561.62 on Oct 9, 2026, down 0.65% from the previous close of $565.30.

Share price, past year

1Y +31.25%

52-week range $425.46 – $591.03. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$561.62
Sep 30, 2026$564.95
Aug 31, 2026$572.85
Jul 31, 2026$512.28
Jun 30, 2026$514.94
May 29, 2026$512.64
Apr 30, 2026$524.33
Mar 31, 2026$491.64
Feb 27, 2026$484.35
Jan 30, 2026$489.80
Dec 31, 2025$470.90
Nov 28, 2025$453.11
Oct 31, 2025$431.59

Key statistics

Market cap
$5.10B
P/E (TTM)
8,023.1
EPS (TTM)
$0.07
Revenue (TTM)
$30.68M
Net income (TTM)
$787.37K
Shares outstanding
9.1M
Dividend yield
—
52-week range
$425.46 – $591.03

ImmuCell's market cap is $5.10B, based on a share price of $561.62 and 9.1M shares outstanding as of Jun 30, 2026.

Financials

ImmuCell reported revenue of $27.64M for fiscal 2025, up 4.34% from fiscal 2024.

ImmuCell reported a net loss of $1.04M in fiscal 2025.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
ImmuCell annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$27.64M+4.3%−$1.04M−3.8%−$0.12$1.22M
FY2024ended Dec 31, 2024$26.49M+51.6%−$2.16M−8.1%−$0.26−$107.82K
FY2023ended Dec 31, 2023$17.47M−5.9%−$5.77M−33.1%−$0.75−$6.57M
FY2022ended Dec 31, 2022$18.57M−3.5%−$2.49M−13.4%−$0.32−$5.52M
FY2021ended Dec 31, 2021$19.24M+25.4%−$78.29K−0.4%−$0.01−$1.65M
FY2020ended Dec 31, 2020$15.34M+11.8%−$1.02M−6.7%−$0.14−$2.76M
FY2019ended Dec 31, 2019$13.72M+24.9%−$1.30M−9.4%−$0.19−$1.16M
FY2018ended Dec 31, 2018$10.99M+5.3%−$2.32M−21.1%−$0.42−$2.40M
FY2017ended Dec 31, 2017$10.43M+9.3%−$168.15K−1.6%−$0.03−$16.58M
FY2016ended Dec 31, 2016$9.54M—$508.45K5.3%$0.12−$3.81M
ImmuCell quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$7.19M$1.83M$0.20
Q1 FY2026ended Mar 31, 2026$10.36M$1.94M$0.21
Q4 FY2025ended Dec 31, 2025$7.63M−$2.85M−$0.32
Q3 FY2025ended Sep 30, 2025$5.51M−$139.75K−$0.02
Q2 FY2025ended Jun 30, 2025$6.44M$501.88K$0.06
Q1 FY2025ended Mar 31, 2025$8.07M$1.45M$0.16
Q4 FY2024ended Dec 31, 2024$7.75M$514.56K$0.09
Q3 FY2024ended Sep 30, 2024$6.01M−$701.69K−$0.09

Company profile

Name
ImmuCell Corporation
Ticker
ICCC
Exchange
NASDAQ
Industry (SEC SIC)
In Vitro & In Vivo Diagnostic Substances
Headquarters
56 Evergreen Dr, Portland, ME 04103
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0000811641

Recent SEC filings

Frequently asked questions

What is ImmuCell's stock price?

ImmuCell (ICCC) closed at $561.62 on Oct 9, 2026, down 0.65% from the previous close of $565.30.

What is ImmuCell's market cap?

ImmuCell's market cap is $5.10B, based on a share price of $561.62 and 9.1M shares outstanding as of Jun 30, 2026.

How much revenue does ImmuCell make?

ImmuCell reported revenue of $27.64M for fiscal 2025, up 4.34% from fiscal 2024.

What is ICCC's P/E ratio?

ImmuCell's price-to-earnings ratio is 8,023.1, based on trailing twelve-month diluted EPS of $0.07.

Does ImmuCell pay a dividend?

ImmuCell's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from ImmuCell Corporation's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures